Antibiotic resistance is escalating into a global crisis. The WHO warns drug‑resistant infections could cause 10 million deaths annually by 2050. In this urgent context, antimicrobial peptides (AMPs) are being studied as next‑generation therapeutics that could complement or even replace traditional antibiotics.
What Makes AMPs Different
AMPs are short, positively charged peptides produced across the tree of life — from frogs and insects to humans. They are part of the innate immune system, acting as natural antibiotics.
- Frogs: In 1987, Michael Zasloff discovered magainins in the African clawed frog (Xenopus laevis) after noticing surgical wounds healed in dirty water without infection.
- Insects: Beetles and flies produce defensins to protect against bacterial invasion.
- Humans: Our skin and mucosal surfaces secrete cathelicidins and defensins, forming a first line of defense against pathogens.
- Marine life: Sponges and mollusks produce AMPs to survive in microbe‑rich environments.
Unlike antibiotics that target enzymes, AMPs rupture bacterial membranes through barrel‑stave, toroidal pore, or carpet models. This physical attack makes resistance harder to evolve.
Evolutionary Insights
A 2026 PLOS Biology study led by Matt Barber at the University of Oregon retraced the origins of lactoferricin, an AMP embedded in lactoferrin. By resurrecting ancestral peptides dating back 160 million years, they showed ancient versions could rupture bacterial membranes — sometimes more potently than modern human peptides.
Despite decades of research, only a handful of antimicrobial peptides have made it into clinical use. Daptomycin, approved by the FDA for Gram‑positive infections, remains the most prominent example, while polymyxins B and E (colistin) are used against Gram‑negative bacteria in last‑resort cases .
Other candidates have had mixed outcomes. Pexiganan, derived from frog peptides, advanced to Phase III trials for diabetic foot ulcers but ultimately failed due to delivery challenges (ClinicalTrials.gov). Omiganan showed promise in rosacea studies, with dermatology journals reporting positive results (Journal of Drugs in Dermatology (jddonline)). Meanwhile, Brilacidin demonstrated comparable efficacy to daptomycin in skin infection trials (PubMed)).
A 2025 review in Drug Discovery Today emphasized that while AMPs are generally safe in topical applications, systemic use remains limited. The main barriers are short half‑life, toxicity at higher doses, and the difficulty of delivering peptides effectively to infection sites (ScienceDirect).
Challenges Ahead
The promise of AMPs is tempered by three persistent obstacles. First, stability: peptides degrade quickly in blood, reducing their therapeutic window. Second, toxicity: at high concentrations, AMPs can damage host cells as well as pathogens. Third, delivery: researchers are experimenting with nanocarrier systems to improve bioavailability and ensure peptides reach the site of infection